Anakinra is an anti-inflammatory therapy that targets the cytokines IL-1alpha/beta, which play a role in COVID-19-induced hyperinflammation. Prof. Evangelos Giamarellos-Bourboulis (Attikon University Hospital, Chaidari, Greece; Chair, European Sepsis Alliance) discusses the results from the SAVE-MORE phase 3 trial investigating the long-term benefit of early anakinra treatment in COVID-19 pneumonia patients.
The presentation entitled: ‘Long-term benefit of early anakinra treatment in COVID-19 pneumonia at risk: results of the SAVE-MORE trial’ was presented at the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), 23-26 May 2022.
Questions:
- What were the aims and design of the SAVE-MORE study? (0:39)
- What were the findings of the study? (2:34)
- Based on these findings, where do you see anakinra sitting in the treatment paradigm for COVID-19 and which patients are most likely to benefit from its use? (4:02)
Disclosures: Evangelos Giamarellos-Bourboulis receives honoraria (paid to the University of Athens) from Abbott CH, Brahms, ThermoFisher GmbH Germany, GSK, and Sobi; he is also a consultant for Abbott CH, Fab’nTech, InflaRx GmbH, UCB, Sobi, and Xbiotech Inc; he also receives research grants (paid to the University of Athens) from AbbVie USA, InflaRx GmbH, Novartis, and UCB; he also receives research grants (paid to the Hellenic Institute for the Study of Sepsis) from Abbott CH, bioMérieux France, Johnson & Johnson, MSD, Sobi, and ThermoFisher Brahms GmbH. Evangelos Giamarellos-Bourboulis also received EU research funding from Horizon 2020 ITN European Sepsis Academy (granted to the University of Athens), Horizon 2020 ImmunoSep and RISCin COVID (granted to the Hellenic Institute for the Study of Sepsis), and Horizon 2020 EPIC-CROWN-2 (granted to the Hellenic Institute for the Study of Sepsis).
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
